EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications

Samar M Hammad iD, Maria F Lopes-Virella

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241814015 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Samar M Hammad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 245 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH/NIDDK, Research Service of the Ralph H. Johnson Department of the Veterans Affairs Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sphingolipids play an important role in the development of diabetes, both type 1 and type 2 diabetes, as well as in the development of both micro- and macro-vascular complications. Several reviews have been published concerning the role of sphingolipids in diabetes but most of the emphasis has been on the possible mechanisms by which sphingolipids, mainly ceramides, contribute to the development of diabetes. Research on circulating levels of the different classes of sphingolipids in serum and in lipoproteins and their importance as biomarkers to predict not only the development of diabetes but also of its complications has only recently emerged and it is still in its infancy. This review summarizes the previously published literature concerning sphingolipid-mediated mechanisms involved in the development of diabetes and its complications, focusing on how circulating plasma sphingolipid levels and the relative content carried by the different lipoproteins may impact their role as possible biomarkers both in the development of diabetes and mainly in the development of diabetic complications. Further studies in this field may open new therapeutic avenues to prevent or arrest/reduce both the development of diabetes and progression of its complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceDiabetes Mellitus, Type 2Cardiovascular DiseasesHumansSphingolipidsCeramides

Stichwörter der Autor:innen

cardiovascular diseasediabetesdiabetic complicationsdiabetic kidney diseaseinsulin resistancemetabolic syndromeobesitysphingolipid

Substanzen

SphingolipidsCeramides

Autor:innen und Institutionen

  • Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Division of Endocrinology, Diabetes and Medical Genetics, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
  • Ralph H. Johnson VA Medical Center, Charleston, SC 29425, USA.

ORCID-Profile: Samar M Hammad

Förderung

  • NIDDK NIH HHS
  • NIH/NIDDK
  • Research Service of the Ralph H. Johnson Department of the Veterans Affairs Medical Center
  • MUSC Department of Regenerative Medicine and Cell Biology (SH)

Zitieren

APA

Hammad, S. M., & Lopes-Virella, M. F. (2023). Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241814015

Vancouver

Hammad SM, Lopes-Virella MF. Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241814015

BibTeX
@article{Hammad2023,
  author = {Hammad, Samar M and Lopes-Virella, Maria F},
  title = {Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241814015}
}
Kostenlos starten →